DNA Damage/DNA Repair

Decyclohexanamine-Exatecan is a Camptothecin derivative, compound a, extracted from patent WO2020219287 A1.

MFH290 is a potent and highly selective cyclin-dependent kinase 12/13 (CDK12/13) covalent inhibitor.

CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor.

(S)-TNG260 is an isomer of TNG260.

MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251.

TYA-018 is an orally active, potent and highly selective HDAC6 inhibitor.

GGFG-amide-glycol-amide-Exatecan (Intermediate 2) is an Exatecan derivative and can be used in the synthesis of antibody-drug conjugates (ADCs).

G13KS is a deubiquitinase UCHL1 ligand and inhibitor.

WRN inhibitor 1 (example 7) is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor that inhibits WRN helicase domain activity.

Z4P is a BBB-permeable IRE1 inhibitor (IC50: 1.11 μM).

Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a drug-linker conjugate for ADC.

CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively.

Gly-Mal-GGFG-Deruxtecan 2-droxy propionamide is a camptothecin-deriver and can be used as a drug linker for ADC.

SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively.

5-Azidometl-2'-deoxyuridine (5-AmdU) is a purine nucleoside analog.

5'-DMT-2'-O-TBDMS-N1-Metl-PseudoUridine-CE-Phosphoramidite is a purine nucleoside analog.

2’-Deoxy-N3-metlcytidine driodide is a purine nucleoside analog.

Alpha-Adenosine is a purine nucleoside analog.

Alpha-Guanosine is a purine nucleoside analog.

PARP7-IN-15 (Compound 18) is a PARP7 inhibitor with IC50 of 0.56 nM, that has antitumor activity.

MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity.

KH16 is a potent and low nanomolar HDAC inhibitor.

ZNL-05-044 is a CDK11 inhibitor with an IC50s of 0.23 μM and 0.27 μM against CDK11A and CDK11B, respectively (NanoBRET assay).

UNC9512 is a potent metl-lysine reader p53 binding protein 1 (53BP1) antagonist.